446 related articles for article (PubMed ID: 18779677)
1. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach.
Ettinger B; Hait H; Reape KZ; Shu H
Menopause; 2008; 15(5):885-9. PubMed ID: 18779677
[TBL] [Abstract][Full Text] [Related]
2. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
4. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
5. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
6. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
7. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
8. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
10. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
11. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
[TBL] [Abstract][Full Text] [Related]
12. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
13. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
15. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
16. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
18. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]